BPC-157 maked its first appearance in scientific literature in 1992, in an article by the Croatian scientist Predrag Sikiric and his coworkers. Most of the research into BPC-157 is done by Sikiric, and has been sponsored by the Croatian pharmaceutical company Pliva. Financial difficulties prompted Pliva in 2005 to halt the investments in BPC-157. Attempts of Merck, which had been a business partner of Pliva for years, to buy the BPC-157 patents and research, have failed. Even though its future as a drug remain unclear, a few years later web shops specializing in research chemicals began selling it.
How is BPC-157 supplied
BPC-157 is not available as a pharmaceutical product at this time. Standard dosage information is unavailable. As a research chemical, BP-157 is sold as a liquid, or as a powder that has to be dissolved in bacteriostatic water before administration. The most popular version is currently produced by Diagen in Slovenia. At room temperature, BPC-157 can be kept for a few months. In a refrigerator or freezer it can be kept for 6 months and 24 months, respectively.
BPC-157 Side effects
In the scientific literature and experiences of users no side effects of BPC-157 have surfaced yet. However, as this drug has not yet been approved as a pharmaceutical agent its safety, and its propensity for side effects may not be well understood at this time. We want to stress here that we know of only one human study on the effects of BPC-157. That study, which concerned test subjects with mild-to-moderate ulcerative colitis that were given BPC-157 rectally, wasn't published in peer-reviewed literature, but presented at a conference. All the other studies are in vitro or used animal models.
Structural Characteristics of BPC-157
BPC-157 is a peptide - an pentadecapeptide, to put it precisely. It consists of 15 amino acids (Gly Glu Pro Pro Pro Gly Lys Pro Ala Asp Asp Ala Gly Leu Val).
This drug is not available as a pharmaceutical product. Prescribing guidelines are unavailable.
BPC-157 is injected with insulin needles. When used off label, most athletes administer dosages of 200-300 microgram/day to accelerate healing of injuries. They inject 200-300 micrograms subcutaneous or intramuscular (not into the joints) as close as possible to the place where the injury occurred, one, two and sometimes even three times a day. Cycles last for 2-4 weeks, after which most underground sources advise an off-period of 2 weeks. If the injury needs further treatment, another cycle can be started.
No commercial preparations containing BPC-157 are known to exist. This drug is available on the black market in underground manufactured products only.
Wlliam Llewellyn (2017) - Anabolics